Discovery of Potent Nonpeptide Vitronectin Receptor (αVβ3) Antagonists
- 1 July 1997
- journal article
- letter
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 40 (15) , 2289-2292
- https://doi.org/10.1021/jm970205r
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Potent, Selective, Orally Active 3-Oxo-1,4-benzodiazepine GPIIb/IIIa Integrin AntagonistsJournal of Medicinal Chemistry, 1996
- Does Aldosterone-lnduced Cardiac Fibrosis Involve Direct Effects on Cardiac Fibroblasts?Journal of Vascular Research, 1996
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994
- Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonistBioorganic & Medicinal Chemistry, 1994
- The dynamic regulation of integrin adhesivenessCurrent Biology, 1994
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994
- Design and synthesis of a C7 mimetic for the predicted .gamma.-turn conformation found in several constrained RGD antagonistsJournal of Medicinal Chemistry, 1992
- Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptidesJournal of Medicinal Chemistry, 1992
- Arg‐Gly‐Asp constrained within cyclic pentapoptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1FEBS Letters, 1991
- ArgGlyAsp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts*1Experimental Cell Research, 1991